Clinical Trial on Entocid Chewable Tablet for Hyperacidity and Gastroesophageal Reflex Disease

  • Muhammad Daniyal Herbion Pakistan (Pvt.) Ltd., Karachi, Pakistan
  • Zubair Ali Herbion Pakistan (Pvt.) Ltd., Karachi, Pakistan.
  • Khan Usmanghani Herbion Pakistan (Pvt.) Ltd., Karachi, Pakistan

Abstract

Objective: To investigate the therapeutic effects of the herbal medication Entocid chewable Tablet a product of Herbion pharmaceutical on the indications and gastric motility of patients with hyperacidity and gastro esophageal reflux disease (GERD).


Methods: Total 50 patient were selected for this study. The patients were selected using a modified Reflux Disease Questionnaire, which is a validated, self-administered scale that is widely used for the assessment of anti-reflux treatment effects. Patients were advised to take study medicine 2 tablets twice daily after meal for 1 week. We take follow up after 1 week. We select the subjects from Sharafi Goth Govt. Hospital Naik Muhamamd Dispensary.


Results: Entocid Chewable tablets were innocuous and well endured and compact the occurrences of all the evaluated GERD symptoms, with no adverse events requiring withdrawal.


Conclusion: Entocid chewable tablets may provide a harmless and active management for decreasing the symptoms of GERD.

Author Biographies

Muhammad Daniyal, Herbion Pakistan (Pvt.) Ltd., Karachi, Pakistan

Department of Medical Affairs and Training,

Zubair Ali, Herbion Pakistan (Pvt.) Ltd., Karachi, Pakistan.

Department of Medical Affairs and Training, 

Khan Usmanghani, Herbion Pakistan (Pvt.) Ltd., Karachi, Pakistan

Department of Research and Development,

Published
2017-07-07
How to Cite
DANIYAL, Muhammad; ALI, Zubair; USMANGHANI, Khan. Clinical Trial on Entocid Chewable Tablet for Hyperacidity and Gastroesophageal Reflex Disease. RADS Journal of Pharmacy and Pharmaceutical Sciences, [S.l.], v. 5, n. 2, p. 02-07, july 2017. ISSN 2521-8484. Available at: <http://jpps.juw.edu.pk/index.php/jpps/article/view/127>. Date accessed: 25 nov. 2017.